| Category | Key details | Evidence |
|---|---|---|
| Disease name / core definition | **Autosomal Dominant Optic Atrophy Plus (DOA plus, ADOA plus)** is the syndromic/multisystem form of OPA1-related dominant optic atrophy, characterized by progressive retinal ganglion cell and optic nerve degeneration with extra-ocular manifestations. Reviews describe DOA as **OMIM 165500** and DOA plus as **OMIM 125250**. Synonyms/related names include **dominant optic atrophy**, **autosomal dominant optic atrophy**, **Kjer type optic atrophy/Kjer syndrome**, and **syndromic DOA / ADOA plus**. | (pqac-00000004, pqac-00000008, pqac-00000013) |
| Disease identifiers / classification | OMIM identifiers explicitly reported in the evidence: **DOA = 165500**; **ADOA plus = 125250**. The disease is a **Mendelian inherited optic neuropathy** and part of the broader hereditary optic neuropathy group. No MONDO, Orphanet, ICD-10/11, or MeSH identifier was directly available in the retrieved evidence set. | (pqac-00000004, pqac-00000008, pqac-00000002, pqac-00000003) |
| Primary causal gene | **OPA1** (chromosome **3q28–q29/3q29**) is the major disease gene; multiple reviews report that **60–90%** of autosomal dominant optic atrophy cases are due to OPA1 variants, with one review citing **70–90%** and another **60–80%**. OPA1 encodes a mitochondrial dynamin-like GTPase in the inner mitochondrial membrane involved in mitochondrial fusion, cristae structure, oxidative phosphorylation support, mtDNA maintenance, mitophagy, and apoptosis regulation. | (pqac-00000004, pqac-00000006, pqac-00000005, pqac-00000012) |
| Molecular mechanism of DOA plus vs isolated DOA | DOA plus is enriched for **missense variants in the dynamin/GTPase domain** that are thought to act via **dominant-negative effects**, whereas many truncating/deletion/splice variants act through **haploinsufficiency**. A 2025 mechanistic study contrasted **c.1034G>A** with **c.1305+2delGT**, showing the missense variant caused >**60%** mitochondrial fragmentation with greater ROS, cytochrome c release, and apoptosis, versus ~**20%** fragmentation for the splice/deletion model. | (pqac-00000011, pqac-00000005, pqac-00000008) |
| Representative pathogenic / likely pathogenic variants reported in evidence | Examples include **c.2708_2711delTTAG (OPA1delTTAG)**, described as a common recurrent pathogenic deletion; **R445H** (classic DOA-plus-associated missense variant); **c.1034G>A (p.Arg345Gln)**; **c.1305+2delGT**; **~69.86 kb deletion** encompassing OPA1; **V465F** and **V560F**; pediatric cohort variant **c.1406_1407del (p.Thr469LysfsTer16)** newly reported in 2023; fibroblast study variant **p.His42Tyr** in an ADOA plus patient. Variant classes include missense, frameshift deletion, splice-site, and larger copy-number deletion. | (pqac-00000011, pqac-00000005, pqac-00000014, pqac-00000006, pqac-00000008) |
| Inheritance / penetrance / expressivity | Inheritance is **autosomal dominant**. Penetrance is **incomplete** but high; one study cited in a 2025 paper estimated **88% lifetime penetrance** for OPA1 mutation carriers. Expressivity is **markedly variable**, both interfamilial and intrafamilial, ranging from asymptomatic or isolated optic atrophy to severe multisystem disease. | (pqac-00000005, pqac-00000004, pqac-00000006, pqac-00000010) |
| Frequency of DOA plus among OPA1 carriers | Multisystem involvement occurs in about **20%** of OPA1 mutation carriers/patients with DOA according to multiple recent reviews and model papers. One 2021 review cites approximately **25%** with extra-ocular symptoms. | (pqac-00000004, pqac-00000011, pqac-00000010) |
| Typical ocular phenotype | Core ocular phenotype includes **bilateral, insidious, progressive visual loss**, usually beginning in childhood; **dyschromatopsia/color vision defects**; **central or centrocecal scotoma**; **temporal optic disc pallor**; **RNFL thinning**, especially in the papillomacular bundle; and **ganglion cell layer thinning** on OCT. | (pqac-00000004, pqac-00000006, pqac-00000003, pqac-00000005) |
| Age of onset / clinical course | Typical onset is in the **first or second decade of life**, often **early childhood**, with slow progression. Pediatric data: in 11 children with confirmed OPA1 mutations, mean baseline visual acuity was **0.40 logMAR (right eye)** and **0.44 logMAR (left eye)** and remained largely unchanged over follow-up. Some reviews note onset can vary from birth to adulthood in broader ADOA. | (pqac-00000006, pqac-00000004, pqac-00000013) |
| Key extra-ocular phenotypes in DOA plus | Frequently reported extra-ocular manifestations include **sensorineural hearing loss/deafness**, **peripheral neuropathy**, **myopathy**, **ataxia**, **spastic paraplegia**, **chronic progressive external ophthalmoplegia (CPEO)**, **multiple sclerosis-like illness**, **parkinsonism**, **dementia**, and less commonly **cardiomyopathy**. | (pqac-00000004, pqac-00000011, pqac-00000010, pqac-00000001) |
| Hearing-loss phenotype | Hearing loss is the best-established extra-ocular feature and is often **auditory neuropathy spectrum disorder (ANSD)**. In the 2024 mouse study, deafness was described as affecting **about 20% of all DOA plus** cases/patients in background discussion. In a 2026 hearing-loss cohort of **18,475** Japanese patients, **10 individuals from 8 families** carried OPA1 variants; hearing loss was typically **post-lingual**, **progressive**, and **mild-to-moderate**, with missense variants tending toward **DOA-plus phenotypes and ANSD**. | (pqac-00000001, pqac-00000015) |
| Quantitative ophthalmic findings from pediatric OPA1 cohort | In 11 pediatric patients: mean first-visit **RNFL thickness 81.6 µm (right), 80.5 µm (left)**; mean **ganglion cell layer 52.5 µm (right), 52.4 µm (left)**; mean **central macular thickness 229.5 µm (right), 233.5 µm (left)**; **9/11** had bilateral temporal disc pallor; the most common visual field defect was **centrocecal scotoma**. | (pqac-00000006) |
| Diagnostic workup | Diagnosis is based on **neuro-ophthalmic examination** plus **OCT**, **visual field testing**, and **electrophysiology** (e.g., VEP; for hearing, **ABR/ASSR** with preserved **DPOAEs** in ANSD). Molecular confirmation uses **targeted gene panels**, **whole-exome sequencing**, or **sequence/CNV analysis** of OPA1. Family history is often present but not universal. | (pqac-00000006, pqac-00000002, pqac-00000003, pqac-00000015, pqac-00000014) |
| Diagnostic genetics examples from evidence | Pediatric sequencing identified **7 different OPA1 mutations in 11 children**; **8/11** had a positive family history. Research studies used **WES**, targeted sequencing, and Sanger validation; large deletions/CNVs were also detected, showing the need for methods that capture both SNVs/indels and structural variants. | (pqac-00000006, pqac-00000014, pqac-00000005) |
| Pathophysiology summary | OPA1 dysfunction disrupts **mitochondrial inner membrane fusion**, **cristae architecture**, **OXPHOS/bioenergetics**, **mtDNA maintenance**, and **quality control/mitophagy**. Downstream effects include **mitochondrial fragmentation**, **membrane-potential loss**, **ROS increase**, **cytochrome c release**, **apoptosis**, and in some models **impaired autophagic flux** and **premature senescence**. | (pqac-00000004, pqac-00000008, pqac-00000005, pqac-00000014, pqac-00000009) |
| Recent mechanistic developments (2023–2024 priority) | Recent studies expanded disease modeling and mechanisms: **patient-derived iPSC lines** from two DOA patients were generated in 2023 for RGC modeling; a **Drosophila model** in 2024 distinguished **loss-of-function** from **dominant-negative** OPA1 variants; a 2024 fibroblast study linked ADOA plus to **reduced autophagy and premature senescence**; a 2024 mouse model showed adult-onset progressive **auditory neuropathy** with **>40% reduction in Opa1 mRNA**, age-related **mtDNA depletion**, oxidative stress, mitophagy, and impaired autophagic flux. | (pqac-00000008, pqac-00000011, pqac-00000001) |
| Biomarker / translational findings | In chronic hereditary optic neuropathy, serum studies reported elevated **sNfL** and **GFAP** in ADOA and LHON, supporting ongoing neurodegeneration; OCT showed ganglion cell/RNFL loss. These biomarkers are promising but not yet established as disease-specific clinical diagnostics for DOA plus. | (pqac-00000016) |
| Current management | Present management remains largely **supportive**: low-vision rehabilitation/visual aids, genetic counseling, ophthalmic surveillance, and management of syndromic complications such as hearing rehabilitation. For OPA1-related hearing loss/ANSD, hearing aids may provide limited benefit; in one 2026 cohort, **5 patients** had limited hearing-aid benefit and **1 cochlear implant** recipient achieved good speech perception. | (pqac-00000003, pqac-00000015) |
| Pharmacologic therapy under investigation | There is **no approved disease-specific therapy** for DOA/DOA plus. **Idebenone** has preliminary/off-label evidence in OPA1-related DOA; reviews note a “possible beneficial effect” but evidence remains limited and not definitive. Experimental small molecules include **paromomycin**, which rescued mitochondrial fragmentation from **c.1034G>A** in vitro in 2025 proof-of-concept work. | (pqac-00000012, pqac-00000005, pqac-00000013) |
| Advanced / pipeline therapeutics | Investigational strategies include **antisense oligonucleotide TANGO/STK-002** to augment wild-type OPA1 output, **gene replacement**, **CRISPR/gene editing**, mitochondrial-targeted antioxidants/peptides, **NAD+ boosters/metabolic support**, and **mitophagy/fission-fusion modulators**. These are early-stage and not standard of care. | (pqac-00000013, pqac-00000004) |
| Prognosis / burden | Visual prognosis is often poor and lifelong; one review notes **half of all DOA patients fail driving standards and are registered legally blind**. DOA plus adds morbidity through hearing impairment and neurological/muscular complications, contributing to reduced quality of life. | (pqac-00000004) |


*Table: This table summarizes the main clinical, genetic, mechanistic, diagnostic, and treatment features of Autosomal Dominant Optic Atrophy Plus using the retrieved evidence. It is useful as a compact reference for disease knowledge base curation and report drafting.*